Abstract: A complex able to detect an analyte (CRA) comprising a particle expressing on its outer surface a compound having specific binding capability (CDCLS) for the analyte and stably including at least one nucleic acid reporter sequence being univocally associated to the CDCLS; process for its construction and uses thereof.

Abstract: The present invention discloses antibodies or fragments thereof able to bind isolated coronary plaque samples and processes for their production using host cells containing DNA sequences encoding for said antibodies of fragments thereof. Methods for screening ligands to said isolated samples are also described, and compositions containing said antibodies are also provided.

Abstract: The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.

Abstract: The present invention provides novel antibody sequences that bind and neutralize Rubella Virus (RuV). The novel sequences can be used for the medical management of RuV infection, in particular for detecting the virus or for preparing pharmaceutical compositions. The RuV-specific antigens recognized by such antibody sequences can be identified using novel phage libraries that display peptides.

Abstract: The use of monoclonal antibodies Fab28 and Fab49 for the prophylactic or therapeutic treatment of swine-origin influenza A (H1N1) virus (S-OIV) infections is described, the which virus is responsible for the influenza syndrome commonly known as “swine flu”. Moreover, the use of the above-mentioned antibodies for selecting potential vaccines for active immunization against S-OIV is described.

Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.

Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.

Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.

Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.